PATENT CLAIM ANALYSIS

Application Number: 15964423
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-09
Patent Classification: ["424", "093200"]

Abstract:
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.

Claim (Index 5):
The method of  claim 1 , wherein said chimeric antigen receptor comprises a signal peptide.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.51163
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15864984', '15865089', '15964446', '15865075', '15864947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8738994474790048
- 35 USC 102 Novelty (BERT): 0.699178975087897
- Combined Prediction Score: 0.856427400239894
- Mean Citation Score: 799.221974
- Max Citation Score: 800.19635
- Similarity Product: 698.1936387389989

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test